Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study
These findings suggest that PMI is both an indicator of prognosis and a surrogate marker of immunocompetence in predicting the clinical response to ICI therapy.
Authors
- Takuya Tsunoda (ORCID: https://orcid.org/0000-0002-6416-8211)
- Toshiaki Tsurui (ORCID: https://orcid.org/0000-0002-6167-8953)
- Yutaro Kubota (ORCID: https://orcid.org/0000-0002-2917-8764)
- Kiyoshi Yoshimura (ORCID: https://orcid.org/0000-0003-4816-1826)
- Hirotsugu Ariizumi (ORCID: https://orcid.org/0000-0003-1663-8730)
- Ryotaro Ohkuma (ORCID: https://orcid.org/0000-0003-4121-2491)
- Atsushi Horiike (ORCID: https://orcid.org/0000-0002-1632-3125)
- Tomoyuki Ishiguro
- Kazuyuki Hamada (ORCID: https://orcid.org/0000-0003-0516-9772)
- Masahiro Shimokawa (ORCID: https://orcid.org/0000-0002-8645-4112)
- Satoshi Wada (ORCID: https://orcid.org/0000-0001-6528-5914)
- Nana Iriguchi
- Yuya Hirasawa
- Mayumi Tsuji (ORCID: https://orcid.org/0000-0002-9579-4418)
- Emiko Mura
- Yuji Kiuchi
- Risako Suzuki
Institutions
- SHOWA Medical University (JP)
- Fukushima Medical University (JP)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-02-06
- DOI
- https://doi.org/10.3389/fonc.2025.1499650
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00